The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon

This prospective double-blind randomized control trial seeks to compare a single formulation
of BoNT, aboboutlinum toxin A (Dysport), to a placebo saline group, studying the effect of
BoNT on Raynaud's symptoms among a more diverse population to provide insight into the
patients most likely to benefit from BoNT.

Inclusion Criteria:

- Male or female adult between 18 and 80 years of age

- Must have health insurance

- Must have a current diagnosis of Raynaud's phenomenon

Exclusion Criteria:

- Allergy to abobotulinum toxin A or its components

- Diagnosis of myasthenia gravis

- Previously received abobotulinum toxin vaccine

- Previously undergone upper extremity vascular surgery (including surgical
sympathectomy)

- Currently receiving aminoglycoside antibiotics

- Received abobotulinum toxin A treatment in either hand in the past 6 months

- Pregnant women

- Women currently breastfeeding

- Current tobacco smoker (use in the past 12 months)

- Unable to read and speak English

- Adults unable to consent

- Individuals who are not yet adults (infants, children, teenagers)

- Prisoners